<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The predominant colonic <z:chebi fb="0" ids="26666">short chain fatty acids</z:chebi>, <z:chebi fb="49" ids="30089,47622">acetate</z:chebi>, <z:chebi fb="0" ids="17272">propionate</z:chebi>, and <z:chebi fb="0" ids="17968">butyrate</z:chebi>, are oxidised into <z:chebi fb="97" ids="29325">CO2</z:chebi> in colonocytes from rat and humans in the preferred order of <z:chebi fb="0" ids="17968">butyrate</z:chebi> (C4) &gt; <z:chebi fb="0" ids="17272">propionate</z:chebi> (C3) &gt; <z:chebi fb="49" ids="30089,47622">acetate</z:chebi> (C2)- hence <z:chebi fb="0" ids="17968">butyrate</z:chebi> is considered to be the principal oxidative substrate for colonocytes </plain></SENT>
<SENT sid="1" pm="."><plain>AIMS: To compare colonocyte oxidation of <z:chebi fb="0" ids="31011">valerate</z:chebi> (C5), <z:chebi fb="0" ids="17120">hexanoate</z:chebi> (C6), and <z:chebi fb="0" ids="25646">octanoate</z:chebi> (C8) with that of <z:chebi fb="0" ids="17968">butyrate</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Isolated rat colonocytes were incubated in the presence of a concentration range of 1-14C labelled C2-C8 fatty acids </plain></SENT>
<SENT sid="3" pm="."><plain>Oxidation rates were obtained by quantifying the production of 14CO2, and Vmax (maximum velocity) and K(m) (Michaelis-Menten constant) were calculated by computer fitting of the data to a Michaelis-Menten plot </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The K(m) value of <z:chebi fb="49" ids="30089,47622">acetate</z:chebi> (0.56 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e> 0.02) mmol/l) was about fourfold higher than the K(m) of <z:chebi fb="0" ids="17968">butyrate</z:chebi> (0.13 (0.01) mmol/l), whereas the K(m) values of <z:chebi fb="0" ids="31011">valerate</z:chebi> (0.19 (0.01) mmol/l), <z:chebi fb="0" ids="17120">hexanoate</z:chebi> (0.19 (0.01) mmol/l), and <z:chebi fb="0" ids="25646">octanoate</z:chebi> (0.16 (0.01) mmol/l) were of the same order of magnitude as the K(m) of <z:chebi fb="0" ids="17968">butyrate</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="49" ids="30089,47622">Acetate</z:chebi> did not influence <z:chebi fb="0" ids="17968">butyrate</z:chebi> oxidation, whereas <z:chebi fb="0" ids="17968">butyrate</z:chebi> strongly inhibited the oxidation of <z:chebi fb="49" ids="30089,47622">acetate</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>By contrast, <z:chebi fb="0" ids="31011">valerate</z:chebi>, <z:chebi fb="0" ids="17120">hexanoate</z:chebi>, and <z:chebi fb="0" ids="25646">octanoate</z:chebi> inhibited colonocyte oxidation of <z:chebi fb="0" ids="17968">butyrate</z:chebi> equally or more than the reverse inhibitory effect of <z:chebi fb="0" ids="17968">butyrate</z:chebi> on <z:chebi fb="0" ids="31011">valerate</z:chebi>, <z:chebi fb="0" ids="17120">hexanoate</z:chebi>, and <z:chebi fb="0" ids="25646">octanoate</z:chebi> oxidation </plain></SENT>
<SENT sid="7" pm="."><plain>The maximum rates of ATP production were in the order of <z:chebi fb="0" ids="31011">valerate</z:chebi> &gt; <z:chebi fb="0" ids="25646">octanoate</z:chebi> = <z:chebi fb="0" ids="17120">hexanoate</z:chebi> &gt; <z:chebi fb="0" ids="17968">butyrate</z:chebi> &gt; <z:chebi fb="49" ids="30089,47622">acetate</z:chebi> (28.47 (0.70), 21.78 (0.75), 21.33 (0.78), 16.12 (0.49), 9.09 (0.34) (mumol/min/g) respectively) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="31011">Valerate</z:chebi>, <z:chebi fb="0" ids="17120">hexanoate</z:chebi>, and <z:chebi fb="0" ids="25646">octanoate</z:chebi> seem to be excellent substrates for colonocyte oxidation, similar to <z:chebi fb="0" ids="17968">butyrate</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>These results may influence the choice of fatty acid composition in enemas used for treatment of patients in whom deficient colonocyte oxidation is suspected-for example, patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> and diversion <z:hpo ids='HP_0002583'>colitis</z:hpo> </plain></SENT>
</text></document>